From: Efficacy and safety of nasal high-flow oxygen in COPD patients
STIT-1 | STIT-2 | STIT-1 + 2 | |
---|---|---|---|
Patient demographics | |||
Sample size (n) | 50 | 27 | 77 |
Sex (male/female) | 42/8 | 15/12 | 57/20 |
Age, years (mean ± SD) | 67.2 ± 8.5 | 64.4 ± 8.2 | 66.2 ± 8.5 |
FEV1 group: 30–50% (n) | 31 | 7 | 38 |
FEV1 group: < 30% (n) | 19 | 20 | 39 |
Lung function | |||
pred. FEV1, % (mean ± SD) | 34.5 ± 11.2 | 24.9 ± 9.2 | 31.0 ± 11.4 |
LTOT, O2 L/min (mean ± SD) | 2.2 ± 1.7 | 2.4 ± 1.4 | 2.2 ± 1.6 |
PaO2, mmHg (mean ± SD) | 51.0 ± 6.1 | 47.0 ± 5.6 | 49.6 ± 6.2 |
PaCO2, mmHg (mean ± SD) | 40.0 ± 4.1 | 49.1 ± 5.4 | 43.2 ± 6.3 |
SpO2 (%) | 91 ± 2 | 89 ± 3 | 91 ± 2 |